RU2013114993A - Композиция каспофунгина - Google Patents
Композиция каспофунгина Download PDFInfo
- Publication number
- RU2013114993A RU2013114993A RU2013114993/15A RU2013114993A RU2013114993A RU 2013114993 A RU2013114993 A RU 2013114993A RU 2013114993/15 A RU2013114993/15 A RU 2013114993/15A RU 2013114993 A RU2013114993 A RU 2013114993A RU 2013114993 A RU2013114993 A RU 2013114993A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- caspofungin
- composition according
- composition
- lactate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 28
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical group C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 title claims abstract 20
- 229960003034 caspofungin Drugs 0.000 title claims abstract 18
- 108010020326 Caspofungin Proteins 0.000 title claims abstract 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 13
- 239000006172 buffering agent Substances 0.000 claims abstract 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 9
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims abstract 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 4
- 229930195725 Mannitol Natural products 0.000 claims abstract 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract 4
- 229930006000 Sucrose Natural products 0.000 claims abstract 4
- 239000000594 mannitol Substances 0.000 claims abstract 4
- 235000010355 mannitol Nutrition 0.000 claims abstract 4
- 239000005720 sucrose Substances 0.000 claims abstract 4
- 159000000021 acetate salts Chemical class 0.000 claims abstract 2
- 239000003963 antioxidant agent Substances 0.000 claims abstract 2
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 150000003893 lactate salts Chemical group 0.000 claims abstract 2
- 239000003755 preservative agent Substances 0.000 claims abstract 2
- 150000003890 succinate salts Chemical group 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 238000010790 dilution Methods 0.000 claims 3
- 239000012895 dilution Substances 0.000 claims 3
- 241000233866 Fungi Species 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 241000228212 Aspergillus Species 0.000 claims 1
- 241000228197 Aspergillus flavus Species 0.000 claims 1
- 241001225321 Aspergillus fumigatus Species 0.000 claims 1
- 241000228245 Aspergillus niger Species 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 241000222178 Candida tropicalis Species 0.000 claims 1
- 240000002355 Celtis tournefortii var. glabrata Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 241000235645 Pichia kudriavzevii Species 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 230000003385 bacteriostatic effect Effects 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38433310P | 2010-09-20 | 2010-09-20 | |
| US61/384,333 | 2010-09-20 | ||
| PCT/EP2011/066202 WO2012038371A1 (en) | 2010-09-20 | 2011-09-19 | Caspofungin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013114993A true RU2013114993A (ru) | 2014-10-27 |
Family
ID=44677877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013114993/15A RU2013114993A (ru) | 2010-09-20 | 2011-09-19 | Композиция каспофунгина |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20120101030A1 (enExample) |
| EP (1) | EP2618814B1 (enExample) |
| JP (1) | JP5914486B2 (enExample) |
| KR (1) | KR20130136466A (enExample) |
| CN (1) | CN103118663A (enExample) |
| AU (1) | AU2011304408B2 (enExample) |
| CA (1) | CA2810112A1 (enExample) |
| DK (1) | DK2618814T3 (enExample) |
| ES (1) | ES2593727T3 (enExample) |
| HR (1) | HRP20161236T1 (enExample) |
| HU (1) | HUE030464T2 (enExample) |
| IL (1) | IL225339A0 (enExample) |
| MX (1) | MX2013003045A (enExample) |
| PL (1) | PL2618814T3 (enExample) |
| PT (1) | PT2618814T (enExample) |
| RS (1) | RS55216B1 (enExample) |
| RU (1) | RU2013114993A (enExample) |
| UA (1) | UA111599C2 (enExample) |
| WO (1) | WO2012038371A1 (enExample) |
| ZA (1) | ZA201302113B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103212059A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲液的组合物 |
| CN103212058A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲剂的组合物 |
| CA2888625A1 (en) | 2012-11-20 | 2014-05-30 | Fresenius Kabi Usa, Llc | Caspofungin acetate formulations |
| CN103142997A (zh) * | 2013-03-13 | 2013-06-12 | 浙江海正药业股份有限公司 | 含有抗真菌剂和琥珀酸盐缓冲液的药物组合物 |
| KR20140123782A (ko) * | 2013-04-15 | 2014-10-23 | 에스케이케미칼주식회사 | 카스포펀진 및 완충제를 포함하는 안정성이 개선된 약학적 조성물 |
| CN104116716A (zh) * | 2013-04-25 | 2014-10-29 | 四川海思科制药有限公司 | 一种含卡泊芬净的冻干粉针剂药物组合物 |
| WO2015052115A1 (en) * | 2013-10-07 | 2015-04-16 | Galenicum Health S.L. | Stable pharmaceutical formulations of caspofungin |
| GR1008818B (el) * | 2015-05-22 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου |
| CN108760937B (zh) * | 2018-07-27 | 2020-12-29 | 杭州华东医药集团新药研究院有限公司 | 醋酸卡泊芬净中残留乙二胺的测定及其应用 |
| CN109758426B (zh) * | 2019-01-24 | 2021-04-27 | 四川制药制剂有限公司 | 一种注射用醋酸卡泊芬净药物组合物及其制备方法 |
| CN110859950B (zh) * | 2019-11-25 | 2021-08-10 | 武汉大学 | 一种用于白念珠菌棘白菌素类药物耐药菌的药物组合物及其应用 |
| EP4364566A1 (en) * | 2022-11-04 | 2024-05-08 | B. Braun Melsungen AG | Anti-fungal composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7673991A (en) * | 1990-03-30 | 1991-10-30 | Smithkline Beecham Corporation | Method for treating fungal infection |
| US5378894A (en) | 1991-12-11 | 1995-01-03 | Kabushiki Kaisha Toshiba | X-ray detector including scintillator channel separator capable of improving sensitivity of X-ray detector |
| US5378804A (en) | 1993-03-16 | 1995-01-03 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| US5952300A (en) | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
| US20080046580A1 (en) | 2006-06-29 | 2008-02-21 | Nokia Corporation | Account creation system and call processing system |
| CN101516387B (zh) * | 2006-07-26 | 2014-06-04 | 桑多斯股份公司 | 卡泊芬净制剂 |
| ES2401299T5 (es) * | 2006-07-26 | 2016-04-06 | Sandoz Ag | Formulaciones de caspofungina |
| US20100137197A1 (en) | 2007-06-26 | 2010-06-03 | Sachin Mittal | Lyophilized anti-fungal composition |
| EP2285236A1 (en) * | 2008-05-30 | 2011-02-23 | DSM IP Assets B.V. | Use of succinic acid |
| KR20110011704A (ko) | 2008-06-25 | 2011-02-08 | 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 | 카스포펀진 불순물 ａ를 함유하지 않는 카스포펀진 |
-
2011
- 2011-09-19 RU RU2013114993/15A patent/RU2013114993A/ru not_active Application Discontinuation
- 2011-09-19 MX MX2013003045A patent/MX2013003045A/es active IP Right Grant
- 2011-09-19 RS RS20160810A patent/RS55216B1/sr unknown
- 2011-09-19 AU AU2011304408A patent/AU2011304408B2/en not_active Ceased
- 2011-09-19 UA UAA201304481A patent/UA111599C2/uk unknown
- 2011-09-19 EP EP11761049.3A patent/EP2618814B1/en active Active
- 2011-09-19 CA CA2810112A patent/CA2810112A1/en not_active Abandoned
- 2011-09-19 HR HRP20161236TT patent/HRP20161236T1/hr unknown
- 2011-09-19 HU HUE11761049A patent/HUE030464T2/en unknown
- 2011-09-19 PT PT117610493T patent/PT2618814T/pt unknown
- 2011-09-19 KR KR1020137010070A patent/KR20130136466A/ko not_active Ceased
- 2011-09-19 DK DK11761049.3T patent/DK2618814T3/en active
- 2011-09-19 PL PL11761049T patent/PL2618814T3/pl unknown
- 2011-09-19 JP JP2013528699A patent/JP5914486B2/ja not_active Expired - Fee Related
- 2011-09-19 CN CN2011800451119A patent/CN103118663A/zh active Pending
- 2011-09-19 ES ES11761049.3T patent/ES2593727T3/es active Active
- 2011-09-19 WO PCT/EP2011/066202 patent/WO2012038371A1/en not_active Ceased
- 2011-09-20 US US13/237,193 patent/US20120101030A1/en not_active Abandoned
-
2013
- 2013-03-19 IL IL225339A patent/IL225339A0/en unknown
- 2013-03-20 ZA ZA2013/02113A patent/ZA201302113B/en unknown
-
2014
- 2014-11-19 US US14/547,742 patent/US9393307B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012038371A1 (en) | 2012-03-29 |
| UA111599C2 (uk) | 2016-05-25 |
| RS55216B1 (sr) | 2017-02-28 |
| PL2618814T3 (pl) | 2017-01-31 |
| CA2810112A1 (en) | 2012-03-29 |
| EP2618814A1 (en) | 2013-07-31 |
| EP2618814B1 (en) | 2016-07-27 |
| AU2011304408B2 (en) | 2015-01-15 |
| MX2013003045A (es) | 2013-06-24 |
| AU2011304408A1 (en) | 2013-03-28 |
| HUE030464T2 (en) | 2017-05-29 |
| US9393307B2 (en) | 2016-07-19 |
| KR20130136466A (ko) | 2013-12-12 |
| CN103118663A (zh) | 2013-05-22 |
| PT2618814T (pt) | 2016-10-06 |
| ES2593727T3 (es) | 2016-12-12 |
| ZA201302113B (en) | 2014-05-28 |
| IL225339A0 (en) | 2013-06-27 |
| US20150072923A1 (en) | 2015-03-12 |
| DK2618814T3 (en) | 2016-10-10 |
| HRP20161236T1 (hr) | 2016-11-18 |
| US20120101030A1 (en) | 2012-04-26 |
| JP5914486B2 (ja) | 2016-05-11 |
| JP2013537212A (ja) | 2013-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013114993A (ru) | Композиция каспофунгина | |
| JP2013537212A5 (enExample) | ||
| CN107106642B (zh) | 拟肽大环化合物及其制剂 | |
| JP6091596B2 (ja) | 高純度シクロペプチド化合物およびその製造方法と使用 | |
| RU2013152751A (ru) | Лиофилизированный препарат цитотоксических дипептидов | |
| RU2011142843A (ru) | Композиция для лечения рака предстательной железы | |
| CN102614491B (zh) | 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 | |
| CN104448295B (zh) | 聚乙二醇‑多爪寡肽键合的雷帕霉素衍生物 | |
| EA201591027A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| RU2011152514A (ru) | Композиция для лечения доброкачественной гиперплазии простаты | |
| RU2020111026A (ru) | Препараты даптомицина | |
| US9925275B2 (en) | Amphotericin B derivatives | |
| RU2013147739A (ru) | Фармацевтическая композиция | |
| RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
| JP2010517987A (ja) | 塩基性ペプチド及びその複合型抗細菌−抗真菌剤としての使用 | |
| RU2016117959A (ru) | Аналог релаксина человека, его фармацевтическая композиция и его фармацевтическое применение | |
| AR123570A1 (es) | Tratamientos para el edema macular diabético y la agudeza visual disminuida | |
| EA201591233A1 (ru) | Состав-депо для инъекций, включающий оптически активный толваптан, и способ его получения | |
| JP5723031B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物 | |
| RU2013128357A (ru) | Стабильный готовый к применению инъекционный раствор цетрореликса | |
| RU2014102090A (ru) | Композиция, содержащая луковый экстракт и липосомы | |
| US20140371123A1 (en) | Aqueous ophthalmic composition | |
| Fotie et al. | Depsipeptides from microorganisms: a new class of antimalarials | |
| Ding et al. | BG40018: a promising drug candidate for the treatment of invasive fungal infections | |
| WO2018001270A1 (en) | Palbociclib prodrugs and composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161027 |